Tags

Type your tag names separated by a space and hit enter

Factor VII Arg/Gln353 polymorphism determines factor VII coagulant activity in patients with myocardial infarction (MI) and control subjects in Belfast and in France but is not a strong indicator of MI risk in the ECTIM study.
Atherosclerosis. 1996 Jan 05; 119(1):119-27.A

Abstract

This paper describes the relationship of factor VII coagulant activity (FVIIc), FVII Arg/Gln353 genotype and risk of myocardial infarction (MI) in the ECTIM (Etude Cas Témoin sur l'Infarctus du Myocarde) study, a multi-centre case-control study on MI. FVIIc was significantly higher in controls from all four centres: Belfast, Lille, Strasbourg and Toulouse, perhaps because elevated FVIIc may predispose to fatal rather than non-fatal MI. Major influences on FVIIc were FVII Arg/Gln353 genotype, triglyceride and cholesterol levels. There was no significant effect of genotype on MI risk however there was a non-significant trend towards increased MI risk in FVII Arg353 homozygotes. Confirming previous observations, FVIIc was highest in FVII Arg353 homozygotes, intermediate in heterozygotes and lowest in FVII Gln353 homozygotes (except Toulouse cases) these differences being highly statistically significant (except Strasbourg cases P = 0.1). In Belfast, consistent with previous findings, there was significant interaction between FVII Arg/Gln353 genotype and triglyceride level in determining FVIIc, whilst this was absent in the French centres. In conclusion, FVII Arg/Gln353 genotype strongly determines FVIIc although neither factor has a strong impact on MI risk in the ECTIM study.

Authors+Show Affiliations

Department of Medicine, University College London Medical School, UK.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

8929253

Citation

Lane, A, et al. "Factor VII Arg/Gln353 Polymorphism Determines Factor VII Coagulant Activity in Patients With Myocardial Infarction (MI) and Control Subjects in Belfast and in France but Is Not a Strong Indicator of MI Risk in the ECTIM Study." Atherosclerosis, vol. 119, no. 1, 1996, pp. 119-27.
Lane A, Green F, Scarabin PY, et al. Factor VII Arg/Gln353 polymorphism determines factor VII coagulant activity in patients with myocardial infarction (MI) and control subjects in Belfast and in France but is not a strong indicator of MI risk in the ECTIM study. Atherosclerosis. 1996;119(1):119-27.
Lane, A., Green, F., Scarabin, P. Y., Nicaud, V., Bara, L., Humphries, S., Evans, A., Luc, G., Cambou, J. P., Arveiler, D., & Cambien, F. (1996). Factor VII Arg/Gln353 polymorphism determines factor VII coagulant activity in patients with myocardial infarction (MI) and control subjects in Belfast and in France but is not a strong indicator of MI risk in the ECTIM study. Atherosclerosis, 119(1), 119-27.
Lane A, et al. Factor VII Arg/Gln353 Polymorphism Determines Factor VII Coagulant Activity in Patients With Myocardial Infarction (MI) and Control Subjects in Belfast and in France but Is Not a Strong Indicator of MI Risk in the ECTIM Study. Atherosclerosis. 1996 Jan 5;119(1):119-27. PubMed PMID: 8929253.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Factor VII Arg/Gln353 polymorphism determines factor VII coagulant activity in patients with myocardial infarction (MI) and control subjects in Belfast and in France but is not a strong indicator of MI risk in the ECTIM study. AU - Lane,A, AU - Green,F, AU - Scarabin,P Y, AU - Nicaud,V, AU - Bara,L, AU - Humphries,S, AU - Evans,A, AU - Luc,G, AU - Cambou,J P, AU - Arveiler,D, AU - Cambien,F, PY - 1996/1/5/pubmed PY - 1996/1/5/medline PY - 1996/1/5/entrez SP - 119 EP - 27 JF - Atherosclerosis JO - Atherosclerosis VL - 119 IS - 1 N2 - This paper describes the relationship of factor VII coagulant activity (FVIIc), FVII Arg/Gln353 genotype and risk of myocardial infarction (MI) in the ECTIM (Etude Cas Témoin sur l'Infarctus du Myocarde) study, a multi-centre case-control study on MI. FVIIc was significantly higher in controls from all four centres: Belfast, Lille, Strasbourg and Toulouse, perhaps because elevated FVIIc may predispose to fatal rather than non-fatal MI. Major influences on FVIIc were FVII Arg/Gln353 genotype, triglyceride and cholesterol levels. There was no significant effect of genotype on MI risk however there was a non-significant trend towards increased MI risk in FVII Arg353 homozygotes. Confirming previous observations, FVIIc was highest in FVII Arg353 homozygotes, intermediate in heterozygotes and lowest in FVII Gln353 homozygotes (except Toulouse cases) these differences being highly statistically significant (except Strasbourg cases P = 0.1). In Belfast, consistent with previous findings, there was significant interaction between FVII Arg/Gln353 genotype and triglyceride level in determining FVIIc, whilst this was absent in the French centres. In conclusion, FVII Arg/Gln353 genotype strongly determines FVIIc although neither factor has a strong impact on MI risk in the ECTIM study. SN - 0021-9150 UR - https://www.unboundmedicine.com/medline/citation/8929253/Factor_VII_Arg/Gln353_polymorphism_determines_factor_VII_coagulant_activity_in_patients_with_myocardial_infarction__MI__and_control_subjects_in_Belfast_and_in_France_but_is_not_a_strong_indicator_of_MI_risk_in_the_ECTIM_study_ L2 - https://linkinghub.elsevier.com/retrieve/pii/0021-9150(95)05638-6 DB - PRIME DP - Unbound Medicine ER -